140410 — Mezzion Pharma Co Income Statement
0.000.00%
Last trade - 00:00
- KR₩1tn
- KR₩1tn
- KR₩32bn
R2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
Standards: | — | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 17,920 | 28,634 | 26,654 | 30,726 | 31,721 |
Cost of Revenue | |||||
Gross Profit | 2,901 | 7,438 | 3,698 | -313 | 3,884 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 42,643 | 36,165 | 43,451 | 54,057 | 46,059 |
Operating Profit | -24,723 | -7,531 | -16,798 | -23,331 | -14,338 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -22,278 | -12,836 | -13,026 | -35,910 | -12,480 |
Provision for Income Taxes | |||||
Net Income After Taxes | -23,301 | -13,873 | -13,603 | -36,298 | -12,728 |
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | -23,251 | -13,829 | -13,603 | -36,298 | -12,728 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Dilution Adjustment | |||||
Diluted Net Income | -23,251 | -13,829 | -13,603 | -36,298 | -12,728 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -897 | -533 | -510 | -1,001 | -454 |
Dividends per Share |